We are live on ! Find out more
PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS

Delisted

PHAS was delisted on the 2nd of November, 2022.

Back to rankings

15 hedge funds and large institutions have $21.2M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
15
Holders Change
+15
Holders Change %
–
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.4M
2
CAM
Cormorant Asset Management
Massachusetts
+$4.35M
3
RSCM
Rock Springs Capital Management
Maryland
+$3.31M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.58M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$759K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$10.4M +$13.4M +3,370,960 New
CAM
2
Cormorant Asset Management
Massachusetts
$3.39M +$4.35M +1,097,926 New
RSCM
3
Rock Springs Capital Management
Maryland
$2.58M +$3.31M +835,000 New
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$2.01M +$2.58M +651,101 New
Alyeska Investment Group
5
Alyeska Investment Group
Illinois
$592K +$759K +191,602 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$544K +$697K +175,994 New
Millennium Management
7
Millennium Management
New York
$411K +$527K +133,022 New
Citigroup
8
Citigroup
New York
$351K +$450K +113,605 New
DCM
9
DAFNA Capital Management
California
$309K +$396K +100,000 New
USAA
10
United Services Automobile Association
Texas
$286K +$367K +92,614 New
LCM
11
Laurion Capital Management
New York
$167K +$214K +54,072 New
TD Asset Management
12
TD Asset Management
Ontario, Canada
$96K +$124K +31,188 New
BlackRock
13
BlackRock
New York
$79K +$100K +25,309 New
Deutsche Bank
14
Deutsche Bank
Germany
$6K +$8.46K +2,136 New
TRCT
15
Tower Research Capital (TRC)
New York
$1K +$1.62K +408 New

PHAS Hedge Fund Activity: Q4 2018 in Review

15 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q4 2018, worth a combined $21.2M.

Buyers outnumbered sellers: 15 funds opened new PHAS positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Wellington Management Group, opening a new position worth an estimated $13.4M.

  • 15 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q4 2018, up from 0 in Q3 2018.
  • Funds reported $21.2M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q4 2018.
  • 15 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 0 closed out, a net change of +15 holders.
  • The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was Wellington Management Group, an estimated $13.4M added.

Based on aggregated 13F filings for Q4 2018.